Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 14 years, it is emailed twice daily to more than 11,000 pharma industry professionals throughout Australia and NZ.

For just $454.50 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or admin@pharmainfocus.com.au for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Perspective
Whither the GBMA in a biosim dominated market?
The departure of Belinda Wood from the helm of the GBMA presents an opportunity to consider what role this group can play in the future Australian medicines market.
Approvals Action
New heart pain drug registered
Menarini has registered a new heart pain drug while Sanofi continues to add to Clexane options to address its impending patent expiry.
Pipeline Monitor
Gilead scores first win from Kite buyout
Gilead has received its first FDA approval for newly acquired CAR-T Yescarta following its USD12 billion buyout of original sponsor Kite Pharma in August.